[go: up one dir, main page]

NO974510L - Synergistiske blandinger av zidovudin, 1592U89 og 3TC eller FTC - Google Patents

Synergistiske blandinger av zidovudin, 1592U89 og 3TC eller FTC

Info

Publication number
NO974510L
NO974510L NO974510A NO974510A NO974510L NO 974510 L NO974510 L NO 974510L NO 974510 A NO974510 A NO 974510A NO 974510 A NO974510 A NO 974510A NO 974510 L NO974510 L NO 974510L
Authority
NO
Norway
Prior art keywords
ftc
zidovudine
synergistic mixtures
synergistic
mixtures
Prior art date
Application number
NO974510A
Other languages
English (en)
Other versions
NO313787B1 (no
NO974510D0 (no
Inventor
David Walter Barry
Clair Martha Heider St
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO974510(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NO974510D0 publication Critical patent/NO974510D0/no
Publication of NO974510L publication Critical patent/NO974510L/no
Publication of NO313787B1 publication Critical patent/NO313787B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cephalosporin Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
NO19974510A 1995-03-30 1997-09-29 Synergistiske blandinger av 1592U89 og 3TC og eventuelt zidovudin, farmasöytiske formuleringer og produkter inneholdendedem, samt anvendelse av dem NO313787B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (3)

Publication Number Publication Date
NO974510D0 NO974510D0 (no) 1997-09-29
NO974510L true NO974510L (no) 1997-09-29
NO313787B1 NO313787B1 (no) 2002-12-02

Family

ID=26306774

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19974510A NO313787B1 (no) 1995-03-30 1997-09-29 Synergistiske blandinger av 1592U89 og 3TC og eventuelt zidovudin, farmasöytiske formuleringer og produkter inneholdendedem, samt anvendelse av dem
NO2005014C NO2005014I2 (no) 1995-03-30 2005-05-24 En kombinasjon omfattende abakavir, fortrinnsvis i form av et fysiologisk funksjonelt salt og lamivudin, fortrinnsvis i form av et fysiologisk funksjonelt salt

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2005014C NO2005014I2 (no) 1995-03-30 2005-05-24 En kombinasjon omfattende abakavir, fortrinnsvis i form av et fysiologisk funksjonelt salt og lamivudin, fortrinnsvis i form av et fysiologisk funksjonelt salt

Country Status (35)

Country Link
US (1) US6417191B1 (no)
EP (1) EP0817637B1 (no)
JP (1) JP2954357B2 (no)
KR (1) KR100542536B1 (no)
CN (1) CN1103593C (no)
AP (1) AP652A (no)
AT (1) ATE220551T1 (no)
AU (1) AU715213B2 (no)
BR (3) BR9607851B1 (no)
CA (1) CA2216634C (no)
CZ (1) CZ295940B6 (no)
DE (3) DE122005000029I1 (no)
DK (1) DK0817637T3 (no)
EA (1) EA000626B3 (no)
EE (1) EE04047B1 (no)
ES (1) ES2179193T3 (no)
FR (1) FR05C0022I2 (no)
GE (1) GEP20022647B (no)
HU (1) HU224010B1 (no)
IL (1) IL117727A (no)
LU (1) LU91171I2 (no)
MX (1) MX9707316A (no)
MY (1) MY115461A (no)
NL (1) NL300195I2 (no)
NO (2) NO313787B1 (no)
NZ (1) NZ306419A (no)
OA (1) OA10616A (no)
PL (1) PL187085B1 (no)
PT (1) PT817637E (no)
RO (1) RO117995B1 (no)
SI (1) SI0817637T1 (no)
SK (1) SK283825B6 (no)
TR (1) TR199701074T1 (no)
UA (1) UA60293C2 (no)
WO (1) WO1996030025A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727983B2 (en) 1996-06-25 2001-01-04 Glaxo Group Limited Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
EP0979082A1 (en) * 1997-05-17 2000-02-16 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
EP1146882A2 (en) * 1998-05-29 2001-10-24 The University Of Florida Combination of zidovudine (azt) with nucleoside analogs for treatment of feline immunodeficiency virus
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
EA201100293A1 (ru) * 2003-01-14 2011-08-30 Джилид Сайэнс, Инк. Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
EP1692516B1 (en) 2003-10-24 2010-12-01 Immunaid Pty Ltd Method of therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2625047A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
RU2469032C2 (ru) 2006-12-13 2012-12-10 Ф.Хоффманн-Ля Рош Аг Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
US9095519B2 (en) * 2007-02-09 2015-08-04 Alphapharm Pty Ltd Dosage form containing two or more active pharmaceutical ingredients in different physical forms
DK2435825T3 (en) 2009-05-27 2015-10-19 Biotempus Ltd Modes for medical care
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
WO2016023082A1 (en) 2014-08-12 2016-02-18 Monash University Lymph directing prodrugs
JP7118888B2 (ja) 2015-09-08 2022-08-16 モナッシュ ユニバーシティ リンパ指向性プロドラッグ
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP4306524A3 (en) 2017-08-29 2024-09-11 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
WO2021159021A1 (en) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Lipid prodrugs of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
EP0513917B2 (en) * 1991-05-16 2001-03-07 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
AU727983B2 (en) 1996-06-25 2001-01-04 Glaxo Group Limited Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV
AU723877C (en) 1996-06-25 2001-08-23 Glaxo Group Limited Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
AU715213B2 (en) 2000-01-20
HU224010B1 (hu) 2005-04-28
ES2179193T3 (es) 2003-01-16
EE04047B1 (et) 2003-06-16
US6417191B1 (en) 2002-07-09
EP0817637A1 (en) 1998-01-14
LU91171I9 (no) 2018-12-28
IL117727A0 (en) 1996-07-23
GEP20022647B (en) 2002-03-25
CZ309097A3 (cs) 1998-05-13
JPH10511682A (ja) 1998-11-10
NO2005014I2 (no) 2008-02-11
NO2005014I1 (no) 2005-06-06
NO313787B1 (no) 2002-12-02
DE69622386D1 (de) 2002-08-22
HUP9801571A2 (hu) 1999-01-28
EA000626B3 (ru) 2016-04-29
ATE220551T1 (de) 2002-08-15
BR9607851A (pt) 1998-07-21
HK1009401A1 (en) 1999-09-10
DE122005000029I2 (de) 2006-04-27
NL300195I2 (nl) 2005-11-01
EE9700240A (et) 1998-04-15
UA60293C2 (uk) 2003-10-15
OA10616A (en) 2001-03-15
AU5497296A (en) 1996-10-16
IL117727A (en) 1999-11-30
PL187085B1 (pl) 2004-05-31
CZ295940B6 (cs) 2005-12-14
EA199700203A1 (ru) 1998-02-26
LU91171I2 (fr) 2005-07-04
JP2954357B2 (ja) 1999-09-27
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
EP0817637B1 (en) 2002-07-17
BR9607851B1 (pt) 2009-01-13
DE69622386T2 (de) 2003-02-13
FR05C0022I1 (no) 2005-06-10
KR19980703420A (ko) 1998-11-05
NO974510D0 (no) 1997-09-29
CA2216634C (en) 2004-07-20
AP9701089A0 (en) 1997-10-31
PL322532A1 (en) 1998-02-02
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
CN1103593C (zh) 2003-03-26
SI0817637T1 (en) 2002-10-31
AP652A (en) 1998-06-19
EA000626B1 (ru) 1999-12-29
SK129597A3 (en) 1998-07-08
BRPI9607851B8 (pt) 2019-11-05
MY115461A (en) 2003-06-30
CN1185110A (zh) 1998-06-17
HUP9801571A3 (en) 2001-04-28
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
DE122005000029I1 (de) 2005-10-06
DK0817637T3 (da) 2002-11-11
FR05C0022I2 (no) 2005-10-21
BRPI9612992B1 (pt) 2020-08-04
KR100542536B1 (ko) 2006-03-23
RO117995B1 (ro) 2002-12-30
CA2216634A1 (en) 1996-10-03
MX9707316A (es) 1997-11-29

Similar Documents

Publication Publication Date Title
NO974510L (no) Synergistiske blandinger av zidovudin, 1592U89 og 3TC eller FTC
PT964849E (pt) Derivados de sulfonilureia e sua utilizacao no controlo da actovidade da interleucina-1
NO983965D0 (no) Polymer-organoleire-kompositter og deres fremstilling
DK0871656T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
NO933434D0 (no) Piperidinderivater, deres fremstilling og anvendelse
DE69415157D1 (de) Elektrochirurgischer prozessor und anwendung
IS4572A (is) Leysnistýring á ljósopsþrengjandi og ljósopsvíkkandi lyfjum í augnvökvahólfinu.
FI973162L (fi) Liikalihavuutta vastustavia proteiineja
BR9601693A (pt) Composição e seus usos
DE69930647D1 (de) Struktur-analoga von amin-basen und nucleosiden
DK1019358T4 (da) 3,3-diarylpropylaminer, deres anvendelse og fremstilling
FR2744442B1 (fr) Preparation du 1,1,1,3,3-pentachlorobutane et du 1,1,1,3,3,-pentafluorobutane
DK0804078T3 (da) Sammensætning og anvendelse deraf
FI963781L (fi) Eristettyjä, MAGE-3-peräisiä peptidejä, jotka kompleksoivat HLA-A2-molekyylejä, ja niiden käyttöjä
NO981282D0 (no) Calcitriolderivater og deres anvendelser
NO983592D0 (no) Blandinger avledet fra korn av Eugénia Jambolana Lamarck, fremstilling og bruk av blandingene og noen av deres bestanddeler
NO986034D0 (no) Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse
DK60893D0 (da) Piperidinderivater, deres fremstilling og anvendelse
NO933435D0 (no) Piperidinderivater, deres fremstilling og anvendelse
NO972821D0 (no) 1-C-perfluoralkylglycosider, deres fremstilling og anvendelse
NO986035D0 (no) Kombinasjoner omfattende VX478, zidovudin og/eller 1592U89 for anvendelse i
NO890816D0 (no) De-emulgeringsblandinger og fremgangsmaate ved fremstilling og anvendelse derav.
PT101949A (pt) Boneco com elevacao simultania de bracos, pernas e abertura de olhos
KR970007249U (ko) 복식날개 선풍기
TR199501594A2 (tr) Sekerleme malzemelerinin islenmesi.

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: KIVEXA-ABAKAVIR/LAMIVUDIN; NAT. REG. NO/DATE: EU/1/04/298/001/NO-002/NO 20050111; FIRST REG. NO/DATE: EU, EU/1/04/298/001/002 20041222

Spc suppl protection certif: SPC/NO 2005 014

Filing date: 20050524

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: KIVEXA-ABAJAVIR/LAMIVUDIN; NAT. REG. NO/DATE: EU/1/04/298/001/NO-002/NO 20050111; FIRST REG. NO/DATE: EU, EU/1/04/298/001/002 20041222

Spc suppl protection certif: 2005014

Filing date: 20050524

Extension date: 20191222

MK1K Patent expired
SPCK Change in the validity period of an spc

Free format text: PRODUCT NAME: EN KOMBINASJON OMFATTENDE ABAKAVIR, FORTRINNSVIS I FORM AV ET FYSIOLOGISK FUNKSJONELT SALT OG LAMIVUDIN, FORTRINNSVIS I FORM AV ET FYSIOLOGISK FUNKSJONELT SALT; NAT. REG. NO/DATE: EU/1/04/298/001/NO-002/NO 20050111; FIRST REG. NO/DATE: EU, EU/1/04/298/001/002 20041222

Spc suppl protection certif: 2005014

Filing date: 20050524

Extension date: 20190222

SPCX Expiry of an spc

Spc suppl protection certif: 2005014

Effective date: 20200103